Chief Science Officer at RiboMed Biotechnologies; Inc. - Carlsbad, California, United States
RiboMed Biotechnologies, Inc. (RiboMed) is a molecular diagnostic company providing proprietary epigenetic and genetic biomarker tests for applications in Personalized Medicine to detect and treat disease. The current focus of the Company is on the detection of epigenetic biomarkers (DNA methylation) associated with disease initiation, progression and response to drug treatment. RiboMed's CLIA/CAP lab offers testing of brain tumors (gliomas) for MGMT methylation and CIMP to predict drug response. Ribomed is also developing epigenetic based diagnostic tests for endometriosis and ovarian cancer.RiboMed provides products and services for epigenetic research, assay development, disease management and drug development utilizing its proprietary and patented technologies for biomarker detection (Abscription®) and methylated DNA isolation and quantification (MethylMagnet® and MethylMeter®). www.ribomed.com